NASDAQ:CFRX - ContraFect Corporation
$0.44
 $0.01
+3.47%
2:10PM EDT
2019-02-15
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CFRX     avg for
industry  
  avg for
sector  
42 stocks weight:  14. 69   0. 00   0. 00  
42 stocks rank:  3. 81 K 1. 86 K 1. 09 K
# analyst opinions:  4. 00   14. 92   14. 43  

quick ratio:  7. 01   5. 37   1. 81  
current ratio:  7. 24   5. 69   2. 19  

target price low:  0. 27   88. 97   117. 82  
target price avg:  0. 35   115. 19   141. 96  
target price high:  0. 48   143. 40   163. 16  
1-yr high:  2. 82   124. 30   142. 77  
last close:  0. 43   101. 85   127. 84  
50-day avg:  1. 09   98. 27   122. 46  
200-day avg:  1. 80   99. 72   122. 70  
1-yr low:  0. 38   78. 19   100. 16  
volume:  628. 27 K 2. 38 M 4. 64 M
50-day avg volume:  958. 68 K 3. 31 M 4. 94 M
200-day avg volume:  364. 11 K 3. 23 M 4. 28 M

1-day return:  7. 50 % 0. 22 % 0. 48 %
this week return:  10. 26 % 1. 77 % 2. 01 %
12-wk return:  -79. 33 % 6. 56 % 3. 33 %
52-wk return:  -74. 00 % -2. 23 % 14. 35 %

enterprise value (EV):  -6. 63 M 55. 17 B 104. 51 B
market cap:  33. 48 M 49. 01 B 96. 46 B
EBITDA:  -29. 32 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 23   -91. 79   2. 29  
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -48. 38 M 2. 37 B 3. 58 B

shares outstanding:  79. 41 M 607. 99 M 1. 22 B
shares:  54. 49 M 605. 53 M 1. 15 B
shares short:  923. 89 K 11. 62 M 12. 55 M
shares short prior month:  568. 94 K 11. 95 M 13. 44 M
short ratio:  0. 69   4. 82   3. 10  
short % of float:  1. 87 % 6. 19 % 2. 82 %
total cash/share:  0. 47   12. 02   11. 46  
total cash:  37. 60 M 7. 41 B 7. 37 B
free cash flow:  -14. 66 M 95. 99 M 2. 04 B
operating cash flow:  -24. 56 M 164. 74 M 3. 04 B

book value:  -0. 01   14. 43   28. 26  
price/book:  -47. 78   -1. 57   -2. 97  
gross profits:  -482. 80 K 8. 28 B 18. 09 B
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -55. 15 % --- ---
1-yr mean volatility:  -0. 28 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 65   3. 03   4. 09  
forward EPS:  -0. 39   4. 33   6. 99  
P/E:  -0. 66   6. 11   26. 91  
forward P/E:  -1. 06   8. 38   10. 48  
PE/G:  0. 01   0. 37   5. 61  
growth:  -51. 33 % 683. 72 % 104. 79 %
earnings high:  -0. 09   1. 27   1. 66  
earnings avg:  -0. 10   1. 01   1. 53  
earnings low:  -0. 11   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -38. 39 % -3. 27 % 3. 81 %
return on equity:  -278. 31 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  0. 21   1. 21   0. 93  
sharpe (1yr):  -0. 72   0. 06   0. 98  

held % insiders:  7. 63 % 6. 46 % 3. 21 %
held % institutions:  55. 58 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : CFRX
.    + 0.008 =         0.008 :: INITIAL WEIGHT
.   + 300.32 =       300.328 :: inverse volume-to-price addition
.  + 286.425 =       586.752 :: spline projection addition
.  - 223.022 =        363.73 :: poor performance penalty
.    x 0.557 =       202.527 :: one-year gains+dividend factor
.    x 0.972 =         196.9 :: 13 weeks' performance factor
.    x 1.492 =       293.871 :: industry recommendation factor
.    x 0.996 =       292.743 :: return on assets factor
.    x 0.972 =       284.596 :: return on equity factor
.    x 2.728 =       776.337 :: current ratio factor
.     x 1.08 =       838.391 :: quick ratio factor
.    x 1.618 =      1356.274 :: short ratio factor
.    x 1.522 =       2064.55 :: price-to-book factor
.    x 5.663 =     11692.359 :: EBITDA multiple factor
.    x 2.173 =     25410.303 :: P/E weight
.    x 2.209 =     56130.321 :: PE/G factor
.    x 1.402 =     78670.196 :: beta factor
.    x 0.724 =     56995.857 :: sharpe factor
.    x 0.939 =     53519.142 :: target low factor
.    x 0.924 =     49427.526 :: target mean factor
.    x 1.033 =     51069.706 :: target high factor
.    x 1.066 =     54420.532 :: industry 12-weeks return
.    x 0.992 =     53994.893 :: "drift" penalty 2 days ago
.    x 0.994 =     53676.419 :: "drift" penalty 5 days ago
.    x 0.992 =     53245.528 :: overall "drift" factor
.    x 0.998 =     53115.584 :: largest single-day jump factor
.     x 0.06 =       3171.08 :: low price factor
.      x 1.0 =      3171.292 :: factor hist industry gain for week 06
.   cubeRoot =        14.692 :: reduced for readability
.                     14.692 :: FINAL WEIGHT for NASDAQ:CFRX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org